{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T22:18:02Z","timestamp":1779142682758,"version":"3.51.4"},"reference-count":50,"publisher":"BMJ","issue":"12","funder":[{"DOI":"10.13039\/501100006356","name":"University of Southern Denmark","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006356","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Region of Southern Denmark"},{"name":"The Region of Zealand"},{"DOI":"10.13039\/501100009708","name":"The Novo Nordisk Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Herta Christensen\u2019 Foundation"},{"DOI":"10.13039\/501100004954","name":"Augustinus Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004954","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Danish Agency for Science"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2017,10,12]]},"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>We present the protocol for a multifactorial intervention study designed to test whether individualised treatment, based on pathophysiological phenotyping and individualised treatment goals, improves type 2 diabetes (T2D) outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and analysis<\/jats:title><jats:p>We will conduct a prospective controlled multicentre open-label intervention study, drawing on the longitudinal cohort of the Danish Centre for Strategic Research in Type 2 Diabetes (DD2). New clinically diagnosed patients with T2D in the intervention group will be assigned to receive individualised treatment by their general practitioner. Intervention patients will be compared with a matched control cohort of DD2 patients receiving routine clinical care. Among intervention patients, we will first do pathophysiological phenotyping to classify patients into WHO-defined T2D or other specific types of diabetes (monogenic diabetes, secondary diabetes etc). Patients with WHO-defined T2D will then be further subcharacterised by their beta-cell function (BCF) and insulin sensitivity (IS), using the revised homeostatic assessment model, as having either insulinopaenic T2D (high IS and low BCF), classical T2D (low IS and low BCF) or hyperinsulinaemic T2D (low IS and high BCF). For each subtype, a specific treatment algorithm will target the primary pathophysiological defect. Similarly, antihypertensive treatment will be targeted at the specific underlying pathophysiology, characterised by impedance cardiography (relative importance of vascular resistance, intravascular volume and cardiac inotropy). All treatment goals will be based on individual patient assessment of expected positive versus adverse effects. Web-based and face-to-face individualised lifestyle intervention will also be implemented to empower patients to make a sustainable improvement in daily physical activity and to change to a low-carbohydrate diet.<\/jats:p><\/jats:sec><jats:sec><jats:title>Ethics and dissemination<\/jats:title><jats:p>The study will use well-known pharmacological agents according to their labels; patient safety is therefore considered high. Study results will be published in international peer-reviewed journals.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration number<\/jats:title><jats:p>NCT02015130; Pre-results.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2017-017493","type":"journal-article","created":{"date-parts":[[2017,12,11]],"date-time":"2017-12-11T07:40:29Z","timestamp":1512978029000},"page":"e017493","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":20,"title":["Protocol for the specialist supervised individualised multifactorial treatment of new clinically diagnosed type 2 diabetes in general practice (IDA): a prospective controlled multicentre open-label intervention study"],"prefix":"10.1136","volume":"7","author":[{"given":"Jacob Volmer","family":"Stidsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens Steen","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan Erik","family":"Henriksen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00f8ren Gunnar","family":"Friborg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9135-3474","authenticated-orcid":false,"given":"Reimar Wernich","family":"Thomsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas Bastholm","family":"Olesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael Hecht","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henning","family":"Beck-Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2017,12,10]]},"reference":[{"key":"2025031412001590000_7.12.e017493.1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00125-016-4065-6","article-title":"Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21\u00a0years follow-up on the Steno-2 randomised trial","volume":"59","author":"G\u00e6de","year":"2016","journal-title":"Diabetologia"},{"key":"2025031412001590000_7.12.e017493.2","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S2213-8587(16)30010-9","article-title":"The changing face of diabetes complications","volume":"4","author":"Gregg","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025031412001590000_7.12.e017493.3","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-3210"},{"key":"2025031412001590000_7.12.e017493.4","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.22.2.233"},{"key":"2025031412001590000_7.12.e017493.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61969-3"},{"key":"2025031412001590000_7.12.e017493.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802743"},{"key":"2025031412001590000_7.12.e017493.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802987"},{"key":"2025031412001590000_7.12.e017493.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808431"},{"key":"2025031412001590000_7.12.e017493.9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d4169"},{"key":"2025031412001590000_7.12.e017493.10","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/dme.12885","article-title":"Effects of glucose-lowering and multifactorial interventions on cardiovascular and mortality outcomes: a meta-analysis of randomized control trials","volume":"33","author":"Seidu","year":"2016","journal-title":"Diabet Med"},{"key":"2025031412001590000_7.12.e017493.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07037-8"},{"key":"2025031412001590000_7.12.e017493.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"2025031412001590000_7.12.e017493.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806470"},{"key":"2025031412001590000_7.12.e017493.14","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-2271"},{"key":"2025031412001590000_7.12.e017493.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1006524"},{"key":"2025031412001590000_7.12.e017493.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003795"},{"key":"2025031412001590000_7.12.e017493.17","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-S003"},{"key":"2025031412001590000_7.12.e017493.18","doi-asserted-by":"publisher","DOI":"10.4158\/EP10357.RA"},{"key":"2025031412001590000_7.12.e017493.19","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12043"},{"key":"2025031412001590000_7.12.e017493.20","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0002"},{"key":"2025031412001590000_7.12.e017493.21","doi-asserted-by":"publisher","DOI":"10.1038\/srep10147"},{"key":"2025031412001590000_7.12.e017493.22","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.2007.S5"},{"key":"2025031412001590000_7.12.e017493.23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62219-9"},{"key":"2025031412001590000_7.12.e017493.24","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-S081"},{"issue":"Suppl 1","key":"2025031412001590000_7.12.e017493.25","first-page":"A354","article-title":"Pathophysiological phenotypes of clinically diagnosed type 2 diabetes. abstracts of the 74th Scientific Sessions of the American Diabetes Association, June 13\u201317, 2014, San Francisco, California","volume":"63","author":"Stidsen","year":"2014","journal-title":"Diabetes"},{"key":"2025031412001590000_7.12.e017493.26","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-1235"},{"key":"2025031412001590000_7.12.e017493.27","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S2213-8587(15)00389-7","article-title":"Type 2 diabetes via \u03b2-cell dysfunction in east Asian people","volume":"4","author":"Yabe","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025031412001590000_7.12.e017493.28","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.16.2.434"},{"key":"2025031412001590000_7.12.e017493.29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i717"},{"key":"2025031412001590000_7.12.e017493.30","doi-asserted-by":"publisher","DOI":"10.3109\/08037051.2014.868629"},{"key":"2025031412001590000_7.12.e017493.31","doi-asserted-by":"publisher","DOI":"10.1177\/1753944709348236"},{"key":"2025031412001590000_7.12.e017493.32","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1097\/HJH.0000000000000749","article-title":"A randomized and controlled study of noninvasive hemodynamic monitoring as a guide to drug treatment of uncontrolled hypertensive patients","volume":"33","author":"Fadl Elmula","year":"2015","journal-title":"J Hypertens"},{"key":"2025031412001590000_7.12.e017493.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2012.10.001"},{"issue":"Suppl 1","key":"2025031412001590000_7.12.e017493.34","first-page":"7","article-title":"The Danish Centre for Strategic Research in Type 2 Diabetes (DD2) Project: rationale and planned nationwide studies of genetic predictors, physical exercise, and individualized pharmacological treatment","volume":"4","author":"Steffensen","year":"2012","journal-title":"Clin Epidemiol"},{"issue":"Suppl 1","key":"2025031412001590000_7.12.e017493.35","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2147\/CLEP.S30838","article-title":"The Danish Centre for Strategic Research in Type 2 Diabetes (DD2) study: implementation of a nationwide patient enrollment system","volume":"4","author":"Nielsen","year":"2012","journal-title":"Clin Epidemiol"},{"issue":"Suppl 1","key":"2025031412001590000_7.12.e017493.36","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2147\/CLEP.S30082","article-title":"The Danish Centre for Strategic Research in Type 2 Diabetes (DD2): organization of diabetes care in Denmark and supplementary data sources for data collection among DD2 study participants","volume":"4","author":"Thomsen","year":"2012","journal-title":"Clin Epidemiol"},{"key":"2025031412001590000_7.12.e017493.37","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S91125"},{"key":"2025031412001590000_7.12.e017493.38","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2983"},{"key":"2025031412001590000_7.12.e017493.39","first-page":"dyw213","article-title":"Data resource profile: the Danish National Prescription Registry","volume":"46","author":"Potteg\u00e5rd","year":"2017","journal-title":"Int J Epidemiol"},{"issue":"Suppl 1","key":"2025031412001590000_7.12.e017493.40","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/CLEP.S30655","article-title":"The Danish Centre for Strategic Research in Type 2 Diabetes (DD2) study: expected outcome from the DD2 project and two intervention studies","volume":"4","author":"Beck-Nielsen","year":"2012","journal-title":"Clin Epidemiol"},{"key":"2025031412001590000_7.12.e017493.41","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2147\/CLEP.S33042","article-title":"New National Biobank of The Danish Center for Strategic Research on Type 2 Diabetes (DD2)","volume":"4","author":"Christensen","year":"2012","journal-title":"Clin Epidemiol"},{"key":"2025031412001590000_7.12.e017493.42","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/CLEP.S30083","article-title":"The Danish Centre for Strategic Research in Type 2 Diabetes (DD2) study: collection of baseline data from the first 580 patients","volume":"4","author":"Thomsen","year":"2012","journal-title":"Clin Epidemiol"},{"key":"2025031412001590000_7.12.e017493.43","doi-asserted-by":"publisher","DOI":"10.1249\/MSS.0000000000001222"},{"key":"2025031412001590000_7.12.e017493.44","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-004-1451-2"},{"key":"2025031412001590000_7.12.e017493.45","doi-asserted-by":"publisher","DOI":"10.1159\/000343145"},{"key":"2025031412001590000_7.12.e017493.46","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(13)38012-9"},{"key":"2025031412001590000_7.12.e017493.47","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(99)90525-0"},{"issue":"Suppl 1","key":"2025031412001590000_7.12.e017493.48","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/jdi.12490","article-title":"Incretin-based drugs for type 2 diabetes: focus on East Asian perspectives","volume":"7","author":"Seino","year":"2016","journal-title":"J Diabetes Investig"},{"key":"2025031412001590000_7.12.e017493.49","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2147\/CLEP.S97303","article-title":"Implementation of interval walking training in patients with type 2 diabetes in Denmark: rationale, design, and baseline characteristics","volume":"8","author":"Ried-Larsen","year":"2016","journal-title":"Clin Epidemiol"},{"key":"2025031412001590000_7.12.e017493.50","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13102-016-0056-7","article-title":"Criterion validity and reliability of a smartphone delivered sub-maximal fitness test for people with type 2 diabetes","volume":"8","author":"Brinkl\u00f8v","year":"2016","journal-title":"BMC Sports Sci Med Rehabil"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2017-017493","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T19:02:03Z","timestamp":1741978923000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2017-017493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":50,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2017,12,10]]},"published-print":{"date-parts":[[2017,12]]}},"alternative-id":["10.1136\/bmjopen-2017-017493"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2017-017493","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12]]}}}